NovoNordisk_CushmanWakefield_RPF_FINAL

Executive Summary

Cushman & Wakefield is pleased to present our proposal to achieve Novo Nordisk's ("NN") initial strategic ambitions (as per your scope document) and also hope to develop a successful partnership that delivers an optimal real estate solution across the NN portfolio.

At Cushman & Wakefield, we are accustomed to delivering results to clients in the early stages of establishing a centralized approach to real estate. This is our area of expertise; we have the best track record in the industry with these types of clients. In the Life Science sector alone, examples include Pharmaceutical Product Development, Novozymes, Lonza and Dentsply Sirona. Cushman & Wakefield started with a transaction mandate, but subsequently grew the partnership scope by delivering portfolio- wide solutions resulting in significant savings/efficiencies for the clients.

We deliver 100 portfolio transformation plans every year

We understand the journey to becoming your trusted real estate advisor takes time. We welcome the opportunity to take the first step with NN and immediately demonstrate how our expertise and insight will unlock savings/value creation at an individual transaction level. We have already demonstrated this with NN in Copenhagen, Warsaw, and Istanbul. Our proposed Platform and Account Team have been specifically chosen for their Life Science and Transaction Management expertise and a demonstrable track record in delivering results for clients making their first steps into a real estate outsourcing model.

Novo Nordisk | Cushman & Wakefield

2